Not a good buy right now (pre-market ahead of after-hours earnings): the stock is trading near resistance (~129–131) with short-term momentum stretched.
Net income: $127.93M, +27.88% YoY → profitability improved meaningfully.
EPS: $1.92, +29.73% YoY → strong earnings growth.
Gross margin: 29.95%, -4.04% YoY → margin compression is the key quality concern (watch pricing/mix and cost commentary on the upcoming Q4 print).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: becoming more cautious.
2026-01-06: Wells Fargo downgraded to Equal Weight from Overweight; PT $133; cited lack of catalysts and sluggish start to fundamentals.
2026-01-05: BofA kept Neutral; cut PT to $142 from $158; likes long-term Pharma dispensing but sees intermediate-term earnings pressure (emergency medicine slowdown, litigation, China weakness, Beauty profitability).
Wall Street pros: durable long-term Pharma dispensing positioning.
Wall Street cons: near-term catalyst gap + multiple operating headwinds; price targets moving down rather than up.
Wall Street analysts forecast ATR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATR is 148 USD with a low forecast of 133 USD and a high forecast of 172 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ATR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATR is 148 USD with a low forecast of 133 USD and a high forecast of 172 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 123.980
Low
133
Averages
148
High
172
Current: 123.980
Low
133
Averages
148
High
172
Wells Fargo
Overweight -> Equal Weight
downgrade
$133
AI Analysis
2026-01-06
Reason
Wells Fargo
Price Target
$133
AI Analysis
2026-01-06
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo downgraded AptarGroup to Equal Weight from Overweight with a $133 price target. The firm says that while 2025 turned into a more challenging year than it originally expected, Wells is still waiting for a catalyst that will drive a rebound. K-shaped economy remains the firm's top concern as low-end consumer health remains poor. For AptarGroup, Wells sees lack of catalysts to outrun sluggish start of year fundamentals.
BofA
George Staphos
Neutral
downgrade
$158 -> $142
2026-01-05
Reason
BofA
George Staphos
Price Target
$158 -> $142
2026-01-05
downgrade
Neutral
Reason
BofA analyst George Staphos lowered the firm's price target on AptarGroup to $142 from $158 and keeps a Neutral rating on the shares. The firm likes Aptar over the long term, given solid positioning in Pharma dispensing. That said, earnings trends could be impacted in the intermediate term by the slowdown in emergency medicine dispensing, litigation, continued weakness in China, and the sluggish profit trend in Beauty, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATR
